Últimas noticias sobre BioSig Technologies (NASDAQ:BSGM) Bolsa

BioSig Technologies

BioSig Technologies Inc is a medical device technology company with an advanced digital signal processing technology platform, the PURE EP Platform (PURE EP), that delivers insights to electrophysiologists for ablation treatments of cardiovascular arrhythmias. The PURE EP Platform enables electrophysiologists to acquire raw signal data in real-time, absent unnecessary noise or interference, to maximize procedural success and minimize unnecessary inefficiencies.

GameStop Corp.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

BHIL

BSGM

CISO

CLEU

GDHG

HUMA

IMTE

NYXH

ORKA

PTPI

RAPP

SURG

THTX

TXMD

WINT

ZYBT

El premercado de hoy revela fuertes movimientos bursátiles tras informes financieros y aprobaciones clave en sectores críticos.

Las acciones de GameStop (GME) suben alrededor del 13%; Aquí están 20 acciones que se mueven en el premercado

BioSig Technologies Inc

Billionaire investor Ray Dalio recently sounded the alarm on the future of the United States, warning of a breakdown in the global order and the end of America's dominant economic role. In response, Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk challenged Dalio's core claim—suggesting that China, not the U.S., is now the world's true consumption powerhouse.
What Happened: In an X post titled "It's Too Late: The Changes Are Coming," Dalio warned that the global shift away from U.S. economic and geopolitical influence is no longer speculative—it's underway. "Enormous trade and capital imbalances are creating unsustainable conditions and major risks of being cut off," he wrote, citing a growing chorus of global companies planning to reduce reliance on U.S. trade.
Dalio argued that the U.S. cannot indefinitely overconsume and rely on foreign lending. "Assuming that one can sell and lend to the U.S. and get paid back with hard (i.e., not devalued) dollars is naive," he said, calling for "coordinated engineering and implementation" to avoid disorderly collapse.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://t.co/PUUxSqYIv8">https://t.co/PUUxSqYIv8</a>
&mdash; Ray Dalio (@RayDalio) <a href="https://twitter.com/RayDalio/status/1916967796065423688?ref_src=twsrc%5Etfw">April 28, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Musk swiftly pushed back on one of Dalio's central premises. Tesla CEO wrote, "Correction: China is a much bigger consumer of manufactured goods than the United States. This year, Chinese consumers will buy more cars than America and Europe combined."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Correction: China is a much bigger consumer of manufactured goods than the United States. This year, Chinese consumers will buy more cars than America and Europe combined.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1917039295115989453?ref_src=twsrc%5Etfw">April 29, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/25/04/44780489/ray-dalio-foresees-economic-crisis-worse-than-recession-im-worried-about-something-worse-than-a-recession-if-this-isnt-handled-well">Ray Dalio Foresees Economic Crisis Worse Than Recession: &#8216;I&#8217;m Worried About Something Worse Than A Recession, If This Isn&#8217;t Handled Well&#8217;</a>
Why It Matters: Dalio's warning rests on the idea that the U.S. is still the main consumer and debtor at the center of global economic gravity—but Musk's data point upends that. 
If China is now the primary global consumer, the leverage shifts. Dalio sees the U.S. as risking global irrelevance due to unsustainable policies, deteriorating trust, and geopolitical missteps. He points to parallels from history, calling today's trajectory &#8220;contemporary version of the old story of how monetary, domestic political and social, and international geopolitical orders change&#8221;. 
According to CEIC, China's annual household expenditure per capita rose to $4,802.36 in December, up from $4,660.37 in December 2023. Looking ahead, China&#8217;s household disposable income per capita in China is forecast to reach $6,510 in 2025, according to Statista. Meanwhile, total consumer spending is projected to hit $7.73 trillion that same year.
Dalio advocates for &#8220;calm, analytical, and coordinated engineering and implementation, with the imbalances and the needs for self-sufficiencies treated as shared challenges, to produce the "beautiful&#8221; deleveragings and rebalancings that need to take place.&#8221;
Both Dalio and Musk agree that global power is being realigned—but they differ on how and why. Dalio sees the U.S. heading toward financial and geopolitical isolation without serious reform. Musk's rebuttal reframes the issue entirely: the world has already moved on, with China leading global consumption.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/personal-finance/25/04/45030088/elon-musk-said-with-confidence-i-know-more-about-manufacturing-than-anyone-alive-then-the-cybertruck-rolled-out-with-8-recalls-and-a-pr-mess">Elon Musk Said With Confidence &#8216;I Know More About Manufacturing Than Anyone Alive&#8217;—Then the Cybertruck Rolled Out With 8 Recalls And A PR Mess</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Opinion

Economics

General

TSLA

Elon Musk Reacts After Ray Dalio Warns Of US Decline, Says China Has Already Surpassed America As Global Consumption Leader

CommVault Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVLT#NASDAQ">CVLT</a>) sees FY2026 sales of $1.130 billion-$1.140 billion vs $1.10 billion analyst estimate.

Guidance

CVLT

CommVault Systems Sees FY2026 Sales $1.130B-$1.140B vs $1.10B Est

CommVault Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVLT#NASDAQ">CVLT</a>) sees Q1 sales of $266.000 million-$270.000 million vs $263.49 million analyst estimate.

CommVault Systems Sees Q1 Sales $266.000M-$270.000M vs $263.49M Est

Barrington Research analyst Vincent Colicchio maintains Hackett Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCKT#NASDAQ">HCKT</a>) with a Outperform and maintains $36 price target.

Price Target

Analyst Ratings

HCKT

Barrington Research Maintains Outperform on Hackett Group, Maintains $36 Price Target

CommVault Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVLT#NASDAQ">CVLT</a>) reported quarterly earnings of $1.03 per share which beat the analyst consensus estimate of $0.93 by 10.75 percent. This is a 30.38 percent increase over earnings of $0.79 per share from the same period last year. The company reported quarterly sales of $275.04 million which beat the analyst consensus estimate of $262.43 million by 4.81 percent. This is a 23.17 percent increase over sales of $223.29 million the same period last year.

Earnings

Earnings Beats

CommVault Systems Q4 Adj. EPS $1.03 Beats $0.93 Estimate, Sales $275.04M Beat $262.43M Estimate

Contracts

LASE

Laser Photonics Subsidiary CMS Laser Receives Order From An Appliance Co., Terms Not Disclosed

– First Level 1 study comparing an emerging technology head-to-head with RP in men with prostate cancer –
– TULSA had no blood loss and no overnight stay, along with reduced post-procedure pain, and more rapid recovery to baseline activities and overall health –
TORONTO, April 29, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=4qcdgVmyeyBVvdSiebSxSXdNR0TXHVOO24ZA5y4iimTZtyj5SNj50d0o4lqmmZrYJ_GzKhtbdKHjhLT_uF3KvKJv7YzY48A8BOmDl8xPwqQ=">Profound Medical Corp.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROF#NASDAQ">PROF</a>, TSX:<a class="ticker" href="https://www.benzinga.com/stock/PRN#TSX">PRN</a>) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, is pleased to announce initial perioperative data from the Level 1 post-market CAPTAIN trial comparing the safety and efficacy of the TULSA procedure with radical prostatectomy ("RP") in men with organ-confined, intermediate-risk, Gleason Score 7 (Grade Group 2 and 3) prostate cancer.
The positive perioperative results were presented yesterday by Xiaosong Meng, M.D., Ph.D., an Assistant Professor in the Department of Urology at UT Southwestern Medical Center, at the American Urological Association ("AUA") Annual Meeting.

PROF

TSX:PRN

Profound Medical Announces Initial Perioperative Data From Level 1 Post-Market CAPTAIN Trial Comparing Safety, Efficacy Of TULSA Procedure With RP In Men With Gleason Score 7 Prostate Cancer

Australia's Alkane Resources (OTCPK: ALKEF)&nbsp; and Canada's Mandalay Resources (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/MNDJF#OTCQB">MNDJF</a>)&nbsp; have announced a "merger of equals "in an all-share transaction valued at approximately AU$1.01 billion ($707 million), creating a diversified <a target="_blank" href="https://www.benzinga.com/topic/gold" rel="noreferrer noopener">gold</a> and antimony producer with global reach.
The newly combined company will retain the Alkane name and remain listed in Australia, but it will seek a dual listing on the Toronto Stock Exchange.
"The transaction will take Alkane to a new level, bringing together two companies with complementary assets and a shared vision for growth," <a target="_blank" href="https://investors.alkane.com.au/site/pdf/88d00faf-747c-4445-87cc-30f033c213b4/Alkane-amp-Mandalay-Merge-to-Create-Gold-amp-Antimony-Producer.pdf" rel="noreferrer noopener">said</a> Nick Earner, Alkane Managing Director. "Mandalay's two high-quality mines match the attributes of Tomingley: a proven history of consistent production, cash generation and exploration upside."
The merger brings together three producing assets across premier mining jurisdictions. Alkane contributes to the Tomingley gold mine in New South Wales, which is currently ramping up production after an expansion.
Mandalay adds its Costerfield gold-antimony mine in Victoria—Australia's only antimony producer—and the Björkdal underground gold mine in Sweden.
The combined group is projected to produce approximately 160,000 gold-equivalent ounces in 2025, increasing to over 180,000 ounces in 2026. Additionally, all-in sustaining costs (AISC) are forecast to drop from AU$2,750/oz in 2025 to AU$2,160/oz in 2026, reflecting improved scale and efficiency.
Frazer Bourchier, Mandalay's President and CEO, noted the merger "presents a compelling opportunity for Mandalay shareholders to accelerate value creation through increased capital markets scale, liquidity and a growing diversified asset base."
"The transaction aligns with our vision to create a mid-tier gold and antimony producer with mines in premier operating jurisdictions and with our strategy for continued growth," he said.
Alkane's Earner will lead the new entity, headquartered in Australia, while industry veteran Andrew Quinn will lead the board, which comprises three directors nominated by Mandalay and two by Alkane.
The pro forma balance sheet includes a robust cash position of AU$188 million ($120 million) as of March 31, 2025, allowing it to pursue further organic growth and strategic opportunities, including advancing Alkane's Boda-Kaiser copper-gold project.
Mandalay shareholders will receive 7.875 Alkane shares for each share they hold, resulting in a 55% stake in the new company, while Alkane shareholders will retain 45%. The transaction has the unanimous support of both boards and major shareholders and is subject to regulatory, shareholder, and court approvals.
The companies expect the deal to close in the second half of 2025, pending regulatory approvals.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45037180/kobold-metals-prepares-billions-to-develop-ethical-sources-of-critical-metals-in-dr-congo" target="_blank" rel="noreferrer noopener">KoBold Metals Prepares Billions To Develop Ethical Sources Of Critical Metals In DR Congo</a></li>
</ul>
Photo by FOTOGRIN via Shutterstock

Equities

Commodities

Small Cap

Legal

ALKEF

MNDJF

Alkane And Mandalay Combine In A $707 Million 'Merger Of Equals'

President Donald Trump denied that bond market volatility influenced his decision to implement a 90-day tariff pause on U.S. trading partners, <a href="https://www.benzinga.com/25/04/44729384/trump-pauses-tariffs-after-yields-surge-bond-vigilantes-hit-another-homerun-experts-point-to-bond-market-panic-for-reversal">despite significant yield fluctuations</a> that saw the 10-year Treasury yield swing from 3.59% to 4.81% over the past year.
What Happened: &#8220;The bond market was getting the yips, but I wasn&#8217;t,&#8221; Trump <a href="https://time.com/7280114/donald-trump-2025-interview-transcript/">told</a> Time magazine, dismissing speculation that financial market stress prompted the policy reversal. &#8220;I know what we have.&#8221;
The bond market experienced one of its largest short-term moves in recent history during early April, with the 10-year Treasury yield dropping below 4% around April 4 before surging past 4.5% by April 11. Yields move inversely to prices, and higher yields translate to increased borrowing costs affecting mortgages, personal loans, and auto financing.
Market experts had attributed Trump&#8217;s tariff pause to the bond market turbulence. Ed Yardeni of Yardeni Research described the situation as &#8220;bond vigilantes hit another homerun,&#8221; referencing investors who protest inflationary policies by selling <a href="https://www.benzinga.com/25/04/44729384/trump-pauses-tariffs-after-yields-surge-bond-vigilantes-hit-another-homerun-experts-point-to-bond-market-panic-for-reversal">bonds to drive yields higher</a>.
Economist Craig Shapiro <a href="https://www.benzinga.com/25/04/44729384/trump-pauses-tariffs-after-yields-surge-bond-vigilantes-hit-another-homerun-experts-point-to-bond-market-panic-for-reversal">suggested China&#8217;s threats to sell U.S. Treasuries</a> &#8220;basically blew up the bond market and forced the administration to backtrack,&#8221; while Gary Black of The Future Fund LLC pointed to &#8220;chaos in the bond market&#8221; as a key factor in the &#8220;stunning about face on tariffs.&#8221;
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45061797/us-stock-futures-edge-higher-tuesday-expert-warns-of-perfect-volatility-storm-with-major-earnings-and-economic-data-due-this-week">US Stock Futures Edge Higher Tuesday: Expert Warns Of &#8216;Perfect Volatility Storm&#8217; With Major Earnings And Economic Data Due This Week</a>
Why It Matters: The market reaction to Trump&#8217;s initial tariff announcement was severe, pushing the Nasdaq into bear market territory while the S&amp;P 500 and Dow Jones <a href="https://www.benzinga.com/25/04/44729384/trump-pauses-tariffs-after-yields-surge-bond-vigilantes-hit-another-homerun-experts-point-to-bond-market-panic-for-reversal">approached similar declines</a>. When Trump announced the pause via Truth Social, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) surged 10.50% and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) jumped 12.00%.
Trump&#8217;s comments about Federal Reserve Chairman Jerome Powell, whom he called &#8220;Mr. Too Late&#8221; for not cutting interest rates, likely <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44861571/donald-trump-blasts-too-late-and-wrong-fed-chair-powell-but-polymarket-traders-doubt-his-termination-will-come-fast-enough">contributed to market volatility</a>, though Trump has since indicated he doesn&#8217;t plan to remove Powell from his position.
Treasury Secretary Scott Bessent claimed <a href="https://www.benzinga.com/25/04/44729384/trump-pauses-tariffs-after-yields-surge-bond-vigilantes-hit-another-homerun-experts-point-to-bond-market-panic-for-reversal">the tariff pause was part of Trump&#8217;s strategy</a> from the beginning, stating, &#8220;He and I had a long talk. This was his strategy all along.&#8221;
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/04/45058829/jim-cramer-dismisses-recession-panic-says-tariffs-may-sting-but-too-many-jobs-for-economy-to-derail">Jim Cramer Dismisses Recession Panic: Says Tariffs May Sting, But Too &#8216;Many Jobs&#8217; For Economy To &#8216;Derail&#8217;</a></li>
</ul>
Photo Courtesy: Rawpixel.com on Shutterstock.com
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Bonds

Trump Says 'Bond Market Was Getting The Yips, But I Wasn't' Amid Tariff Pause As 10-Year Yield Jumps From 3.59% To 4.81%

Stephens &amp; Co. analyst Daniel Imbro maintains PAMT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAMT#NASDAQ">PAMT</a>) with a Equal-Weight and raises the price target from $11 to $12.5.

PAMT

Stephens & Co. Maintains Equal-Weight on PAMT, Raises Price Target to $12.5

FOUR

Shift4 Payments Sees Q2 Gross Revenue Less Network	Fees Of $405M - $415M

WIIM

ZBRA

Zebra Technologies shares are trading higher after the company reported better-than-expected Q1 financial results.

Shift4 Payments Sees FY25 Gross Revenue Less Network Fees Of $166B - $1.73B

NeoGenomics Raises FY2025 Adj EPS Guidance from $0.15-$0.19 to $0.16-$0.20 vs $0.18 Est

Stephens &amp; Co. analyst Daniel Imbro downgrades Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) from Overweight to Equal-Weight and lowers the price target from $515 to $255.

Downgrades

SAIA

Stephens & Co. Downgrades Saia to Equal-Weight, Lowers Price Target to $255

BBVA

Banco Bilbao Vizcaya Argentaria shares are trading lower. The company reported Q1 financial results.

Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) reported quarterly earnings of $1.07 per share which beat the analyst consensus estimate of $0.71 by 50.7 percent. This is a 98.15 percent increase over earnings of $0.54 per share from the same period last year. The company reported quarterly sales of $848.30 million which missed the analyst consensus estimate of $868.30 million by 2.30 percent. This is a 19.92 percent increase over sales of $707.40 million the same period last year.

Earnings Misses

Shift4 Payments Q1 Adj. EPS $1.07 Beats $0.71 Estimate, Sales $848.30M Miss $868.30M Estimate

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/04/28/final-trades-goldman-sachs-apollo-global-qualcomm-and-check-point.html">Halftime Report Final Trades</a>,&#8221; Stephen L. Weiss of Short Hills Capital Partners named The Goldman Sachs Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) as <a href="https://www.benzinga.com/quote/GS/earnings">his final trade</a>.
On the earnings front, Goldman Sachs reported quarterly earnings of $14.12 per share on April 14, beating the analyst consensus estimate of $12.35 per share. The firm also reported quarterly sales of $15.06 billion, beating the analyst consensus estimate of $14.81 billion.
Bryn Talkington, Managing Partner of Requisite Capital Management, said Apollo Global Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) will release earnings this Friday.
Analysts expect the company to report quarterly earnings at $1.85 per share on revenue of $964.53 million.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Jim Lebenthal of Cerity Partners picked QUALCOMM Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) as his final trade, which is scheduled to release earnings results for its second quarter on Wednesday, April 30, after the closing bell.
Analysts expect the company to report quarterly earnings at $2.81 per share on revenue of $10.65 billion.
Joseph M. Terranova of Virtus Investment Partners picked Check Point Software Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) after last week's selloff following earnings report.
On April 23, the company reported quarterly revenue growth of 7% year over year to $637.8 million, topping the analyst consensus estimate of $636.2 million.
Price Action:
<ul>
<li>Goldman Sachs shares gained 0.3% to close at $546.40 on Monday.</li>
<li>Apollo Global gained 2.2% to close at $136.36 during Monday's session.</li>
<li>Qualcomm shares fell 0.6% to close at $147.62 on Monday.</li>
<li>Check Point Software shares climbed 2.8% to settle at $212.41 during the session.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45038052/top-2-industrials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Industrials Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

CHKP

QCOM

Goldman Sachs, Qualcomm, Apollo Global And A Tech Stock On CNBC's 'Final Trades'

Novel Gene Therapy Program Offers a Promising Opportunity for Curative Therapy in Diabetes
AUSTIN, Texas, April 29, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4415379-1&amp;h=3725234881&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc.">Genprex, Inc.</a> ("Genprex" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators have been selected to present at the upcoming American Society of Gene and Cell Therapy's (ASGCT) 28th Annual Meeting being held May 13-17, 2025 in New Orleans, Louisiana. The collaborators will present positive preclinical data and research from studies of GPX-002, the Company's diabetes gene therapy drug candidate.

GNPX

Genprex Collaborators To Present Preclinical Data And Research From Studies Of GPX-002, Diabetes Gene Therapy, At ASGCT 28Th Annual Meeting

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health shares are trading higher after the company announced a collaboration with Novo Nordisk to offer a bundled package of all dose strengths of Wegovy on its platform.

Management

Press Releases

BioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent

BioSig Technologies Chief Executive Officer Mr. Anthony Amato Issues the Following Letter to Shareholders

Financing

BioSig Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BioSig Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer

BioSig Technologies Improves Balance Sheet, Announces Reduction in Outstanding Payables during Q2 2024

BioSig Technologies Announces Intent to Acquire the Assets of Neuro-Kinesis Corporation

BioSig Technologies' Common Stock to Resume Trading on the NASDAQ Exchange, Wednesday, October 23, 2024 After Its Successful Appeal to the NASDAQ Panel

BioSig Regains Compliance with Nasdaq's Minimum Bid Price Requirement

BioSig Technologies Confirms Full Compliance with Nasdaq Requirements for Continued Listing on The Nasdaq Capital Market

Comments

BioSig Technologies

Noticias

Últimas noticias sobre BioSig Technologies (NASDAQ:BSGM) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL